Bioventus (BVS) Income from Non-Controlling Interests (2020 - 2026)
Bioventus' (BVS) quarterly Income from Non-Controlling Interests came in at $744000.0 in Q1 2026, up 208.61% YoY from $241078.5 in Q1 2025, and up 137.59% on a QoQ basis from -$2.0 million in Q4 2025.
Bioventus (BVS) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Bioventus (BVS) has 7 years of Income from Non-Controlling Interests data on file, last reported at $744000.0 in Q1 2026.
- Quarterly Income from Non-Controlling Interests rose 208.61% year-over-year to $744000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 41.2% YoY) and the FY2023 annual result came in at -$24.5 million, down 75.26% from the prior year.
- Income from Non-Controlling Interests advanced to $744000.0 in Q1 2026, from -$2.0 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $10.7 million in Q4 2024 to a low of -$14.9 million in Q2 2023.
- A 5-year average of -$2.4 million and a median of -$1.5 million in 2023 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2022 — Income from Non-Controlling Interests slumped 764.95% — and 2024, when it soared 786.47%.
- Tracing BVS's Income from Non-Controlling Interests over 5 years: stood at -$4.7 million in 2022, then surged by 66.84% to -$1.6 million in 2023, then jumped by 786.47% to $10.7 million in 2024, then slumped by 118.48% to -$2.0 million in 2025, then surged by 137.59% to $744000.0 in 2026.
- The last three Income from Non-Controlling Interests figures came in at $744000.0 (Q1 2026), -$2.0 million (Q4 2025), and $601000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | - |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | - |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 16.00 Mn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | -2.00 Mn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -500,000.00 |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 13.00 Mn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 2.32 Mn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 900,000.00 |
| 10 | Bioventus | 972.56 Mn | 943.11 Mn | 105.67 Mn | 2.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | 2.98 Mn |
| Mar 28, 2026 | 744,000.00 |
| Dec 31, 2025 | -1.98 Mn |
| Sep 27, 2025 | 601,000.00 |
| Jun 28, 2025 | 1.81 Mn |
| Mar 29, 2025 | -685,000.00 |
| Dec 31, 2024 | 10.71 Mn |
| Sep 28, 2024 | -570,000.00 |
| Jun 29, 2024 | -8.62 Mn |
| Mar 30, 2024 | -1.49 Mn |
| Dec 31, 2023 | -1.56 Mn |
| Apr 1, 2023 | -14.94 Mn |
| Dec 31, 2022 | -4.70 Mn |
| Oct 1, 2022 | -9.25 Mn |
| Apr 2, 2022 | -3.53 Mn |
| Dec 31, 2021 | 8.26 Mn |
| Oct 2, 2021 | -1.30 Mn |
| Jul 3, 2021 | -6.65 Mn |
| Apr 3, 2021 | -408,000.00 |
| Dec 31, 2020 | -525,000.00 |